Skip to main content

Table 5 Effects of zafirlukast on sputum inflammatory indices in paired samples

From: Tolerance and rebound with zafirlukast in patients with persistent asthma

  Zafirlukast (n = 9) Placebo (n = 11)
  Baseline 12 weeks Baseline 12 weeks
*TCC × 10 3 /ml 38.8 (0.6–293.8) 22.8 (0.3–93.8) 41.0 (0.5–176) 41.5 (3.8–109.3)
Sputum eosinophils, % 5.8 (0.8–39.2) 4.0 (0.4–54.6) 5.3 (0.2–14.7) 1.7 (0–39.5)
CysLT pg/ml 331 (182–648) 567 (151–1029) 192 (15–763) 412 (49–1332)
PGE 2 pg/ml 942 (572–1951) 1276 (836–2513) 1245 (479–6155) 959.2 (329–3756)
  1. *Data are expressed as median and (range).